Intuitive Surgical, Inc. (NASDAQ:ISRG) Shares Sold by Redmile Group LLC

Redmile Group LLC lessened its stake in Intuitive Surgical, Inc. (NASDAQ:ISRG) by 45.5% in the first quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 29,546 shares of the medical equipment provider’s stock after selling 24,712 shares during the period. Redmile Group LLC’s holdings in Intuitive Surgical were worth $11,792,000 at the end of the most recent quarter.

Several other large investors have also recently bought and sold shares of the stock. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA lifted its holdings in shares of Intuitive Surgical by 0.3% during the fourth quarter. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA now owns 8,899 shares of the medical equipment provider’s stock worth $3,002,000 after buying an additional 27 shares during the last quarter. Advance Capital Management Inc. raised its holdings in shares of Intuitive Surgical by 3.8% in the 1st quarter. Advance Capital Management Inc. now owns 740 shares of the medical equipment provider’s stock worth $295,000 after buying an additional 27 shares in the last quarter. Perigon Wealth Management LLC lifted its holdings in shares of Intuitive Surgical by 0.5% during the first quarter. Perigon Wealth Management LLC now owns 5,363 shares of the medical equipment provider’s stock valued at $2,140,000 after acquiring an additional 27 shares during the period. Sheaff Brock Investment Advisors LLC boosted its position in Intuitive Surgical by 1.3% in the fourth quarter. Sheaff Brock Investment Advisors LLC now owns 2,226 shares of the medical equipment provider’s stock valued at $751,000 after buying an additional 29 shares in the last quarter. Finally, Sugarloaf Wealth Management LLC boosted its holdings in shares of Intuitive Surgical by 5.7% in the 1st quarter. Sugarloaf Wealth Management LLC now owns 534 shares of the medical equipment provider’s stock worth $213,000 after acquiring an additional 29 shares in the last quarter. Institutional investors and hedge funds own 83.64% of the company’s stock.

Intuitive Surgical Stock Performance

ISRG traded up $2.36 during trading hours on Monday, reaching $443.66. The company’s stock had a trading volume of 1,120,437 shares, compared to its average volume of 1,558,931. The company’s 50-day moving average is $428.69 and its 200-day moving average is $399.37. The firm has a market cap of $157.65 billion, a PE ratio of 80.08, a price-to-earnings-growth ratio of 4.86 and a beta of 1.39. Intuitive Surgical, Inc. has a 52 week low of $254.85 and a 52 week high of $468.78.

Intuitive Surgical (NASDAQ:ISRG) last released its quarterly earnings results on Thursday, July 18th. The medical equipment provider reported $1.78 earnings per share for the quarter, topping the consensus estimate of $1.54 by $0.24. The business had revenue of $2.01 billion during the quarter, compared to analysts’ expectations of $1.97 billion. Intuitive Surgical had a return on equity of 13.04% and a net margin of 27.65%. The firm’s revenue for the quarter was up 14.5% compared to the same quarter last year. During the same period last year, the firm posted $1.18 EPS. Equities analysts anticipate that Intuitive Surgical, Inc. will post 5.22 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, Director Craig H. Barratt sold 1,400 shares of the firm’s stock in a transaction on Tuesday, July 23rd. The stock was sold at an average price of $458.13, for a total value of $641,382.00. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. In other news, EVP Myriam Curet sold 2,818 shares of the company’s stock in a transaction on Tuesday, July 23rd. The shares were sold at an average price of $458.13, for a total transaction of $1,291,010.34. Following the completion of the transaction, the executive vice president now directly owns 298 shares in the company, valued at $136,522.74. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Craig H. Barratt sold 1,400 shares of the company’s stock in a transaction dated Tuesday, July 23rd. The stock was sold at an average price of $458.13, for a total value of $641,382.00. The disclosure for this sale can be found here. Over the last three months, insiders have sold 12,982 shares of company stock valued at $5,451,547. 0.90% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

A number of equities research analysts have commented on ISRG shares. Stifel Nicolaus increased their price objective on shares of Intuitive Surgical from $430.00 to $475.00 and gave the stock a “buy” rating in a report on Friday, July 19th. Barclays raised their target price on Intuitive Surgical from $430.00 to $490.00 and gave the stock an “overweight” rating in a report on Thursday, July 18th. Jefferies Financial Group boosted their price target on shares of Intuitive Surgical from $365.00 to $375.00 and gave the company a “hold” rating in a report on Friday, April 19th. Morgan Stanley increased their target price on Intuitive Surgical from $375.00 to $460.00 and gave the stock an “equal weight” rating in a research note on Monday, July 15th. Finally, Robert W. Baird increased their target price on Intuitive Surgical from $487.00 to $503.00 and gave the stock an “outperform” rating in a report on Friday, July 19th. Six investment analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $438.74.

About Intuitive Surgical

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.